Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANZ 8613 advanced breast cancer endocrine therapy substitution versus addition study
ACTRN12607000096459Phase 3Completed
- Sponsor
- Breast Cancer Trials
- Start
- Mar 1987
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen and medroxyprogesterone acetate in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoints: Response rate, Time to disease progression and 3 more. Started Mar 1987; status: completed.
02
Drugs
tamoxifenmedroxyprogesterone acetate
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000096459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000096459.